鹤壁高级婴儿腿部静脉穿刺模型阳泉高级电子手臂静脉穿刺训练模型（报警装置）,福建高级乳房检查模型,吉安女性内外生殖器解剖模型,南昌不锈钢鼠兔解剖台,乌兰察布仿古针灸铜人,乳牙立体模型,合肥喉结构与功能放大模型

As the COVID-19 vaccine makes its way across the country and into the hands of those who need it most, many nursing homes and senior communities are anxiously waiting as they are the most vulnerable.“I’m a true Okie from Muskogee, Oklahoma,” says 80-year-old Donna. After 46 years, she and her 83-year-old husband Art made the decision to leave the countryside and move into a senior community. They chose one of the 26 Arrow Senior Living communities that are housed around the Midwest. Things were great until the pandemic hit.“Since we live on the independent side, we do our own things. Until this COVID hit, we came and went as we wanted to,”she said.Their way of living is now completely different. No visits with their three sons. No extracurricular activities. They're diligent about masks and about the proper public health measures to prevent the virus.“It's a big concern, we know this is a killer,” Donna said. “Some get a light case and some are asymptomatic and you never who’s going to get the serious case.”Which is why she's anxiously waiting for the vaccine. She remembers when the polio vaccine came out and said it was wonderful."I don’t remember people questioning it, being afraid of having it so much then as some people today but I don’t know why they’d even question it with the horrible pandemic we’ve been having,” Donna said.Stephanie Harris, CEO of Arrow Senior Living said “absolutely” when asked if she would get the vaccine. Harris says her employees will get it too. In all, nearly 4,000 people between residents and staff will need to be vaccinated.“We have been blown away at how overwhelming the response has been by our resident group, over 90% of our residents, when we surveyed them, said ‘yes’ to vaccination,” says Harris.They're not first in line, but they're not far off. They have clinics scheduled for late December, and they're excited.“I’m tired of being cooped up and taking extraordinary precautions to ensure that I could be here in this seat to support our larger operation and I want to be able to get on with some sense of normal,” Harris said.Harris added this recent surge has been brutal and it's taking an emotional toll on everyone.Holiday gatherings have been canceled, important events missed during a time when grandparents should be spending with grandkids. It's caused Arrow Senior Living to take extraordinary precautions, deploying things like mask detection technology to determine whether face coverings are being utilized. There's not one community in their network that hasn't been touched by COVID-19.“This is going to be a strange Christmas, we’re accepting it,” Donna said. “We have three sons but they’re all doing their thing. They didn’t feel like it was safe to travel and we’ll be having Christmas here.” 2789

As millions of Americans avoid routine doctor’s appointments right now for fear of catching COVID-19, a decades-old practice is suddenly gaining new attention: the house call.“The notion of a house call means the care provider can get a more comprehensive view of you as a person,” explained Stacey Chang, who serves as the executive director for the Design Institute for Health.Chang says a reinvention of the house call could be a viable solution to America’s evolving post-coronavirus healthcare system. New portable technology means doctors can do more than just check your temperature.Health officials across the country are also worried that Americans in isolation are avoiding routine check-ups, which could lead to more long-term issues once the pandemic ends.“The care that didn’t happen, the routine care for managing chronic diseases, we may end up having greater mortality from those missed interventions than what COVID itself caused,” Chang added.Aside from keeping people away from hospitals where COVID-19 might be lurking, the house call gives physicians a chance to get to know their patients. Spending more than 10 minutes with someone in an office would give doctors a better chance to treat chronic diseases.“It’s really a relationship between the person that’s caring for you and the person you’re caring for,” Chang said. 1352

AstraZeneca is the latest drugmaker to announce promising Phase 3 trial results from its COVID-19 vaccine candidate.On Monday, AstraZeneca said its two-shot vaccine candidate has been 90% effective thus far along with no safety concerns.“These findings show that we have an effective vaccine that will save many lives," said Professor Andrew Pollard, the chief executive of the study. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply. Today’s announcement is only possible thanks to the many volunteers in our trial, and the hard working and talented team of researchers based around the world.”The company added in its press release that its vaccine candidate offers two distinct advantages over vaccines made by Pfizer and Moderna — it's cheaper to produce, and does not need to be stored in ultra-cold conditions before use.AstraZeneca added that the company would "immediately" prepare regulatory paperwork to seek Emergency Use Listing status from the World Health Organization.AstraZeneca is just the latest drug company to report encouraging results from its COVID-19 vaccine candidate.Last week, Pfizer said it had submitted Emergency Use Authorization paperwork to the Food & Drug Administration (FDA) after a final analysis of its vaccine candidate proved to be 95% effective in preventing COVID-19. The FDA is expected to approve the drug in the coming weeks.Moderna has also said that early results show its vaccine candidate to be 95% effective, and is on track to have the drug approved for Emergency Use Authorization by the end of the year.AstraZeneca, Pfizer and Moderna are all shattering records for vaccine development. The three vaccines are all on track to be approved for widespread use in uder a year. Typically, it takes several years for a vaccine to go from development to approval.The announcement comes as COVID-19 is spreading around the world at a rate not previously seen since the pandemic began. And while all three companies are pre-producing their vaccines in the hope that it will be approved, health experts warn that they won't be widely available until spring 2021. 2247

ATLANTA (AP) — Early in-person voting began Monday in Georgia for the state's two U.S. Senate runoffs.The early voting period runs as late as Dec. 31 in some counties.It could determine the outcome of the races between Republican U.S. Sens. David Perdue and Kelly Loeffler and Democratic challengers Jon Ossoff and Raphael Warnock.A majority of votes before the Nov. 3 general election were cast in person during early voting.The period could be even more important during the runoffs because of the shortened period for voters to request and return ballots by mail.More than 125,000 people cast ballots in October on the first day of early voting. Lines were long then and could be long again Monday. 709

At the end of summer, Christina Curfman would typically be rushing to prepare her second-grade classroom. However, it's different this year.“I started a garden,” said Curfman. “I’ve never planted vegetables my entire life, but my mom always had a garden, and I love it.” Her newfound happiness is coming with just as much heartbreak. “I submitted my retirement papers,” said the teacher of 28 years. It was a tough decision, but with COVID-19 threatening the in-person relationships she loved so much while teaching, she was forced to reconsider going back to school. “I had a student ask me, ‘Is this coronavirus going to kill us all?’ and I was like, ‘Oh my goodness. I’m not doing this anymore.’” Curfman knew her body couldn’t take the risk. “I have an autoimmune disorder. It’s similar to Rheumatoid Arthritis, so I have trouble walking," she explained. "The medications that I take kind of lowers your immune system, too.” On top of that, a few years ago, she spent weeks in the hospital for a blood clot in her lung. “I was saying goodbye to friends and family. It looked pretty dire, it looked like I wasn’t going to make it, and I wasn’t willing to test that again,” recalled Curfman. 1207